Addressing the Challenges of Alzheimer’s Agitation
Advancing IGC-AD1 in the CALMA trial—supporting patients and caregivers through science and compassion.
Our Science, Our Commitment
What is CALMA?
CALMA is a multicenter Phase 2 clinical trial designed to evaluate the safety and potential efficacy of IGC-AD1 for treating agitation in participants with dementia due to Alzheimer's disease.
Explore CALMA →What is IGC-AD1?
IGC-AD1 is IGC Pharma’s lead candidate—a partial CB1 receptor agonist with anti-inflammatory action, designed to address agitation associated with Alzheimer’s disease.
Learn About IGC‑AD1 →Why AI Integration?
Our AI transforms multimodal data into actionable insights, empowering physicians with early Alzheimer’s prediction and more precise clinical decisión support.
Discover MINT‑AD →Latest Press Releases
Explore how IGC Pharma’s data, trials, and milestones are shaping a brighter future for Alzheimer’s care.
IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer’s Research
Together, we’re turning research into resilience, and innovation into care for millions worldwide.
0
Million
People age 65 and older live with Alzheimer's disease today in the US1.
0
Million
People are projected to have Alzheimer's disease by 2060 in the US 1.
0
th
Leading cause of death among all ages in the United States1.
$
0
Trillion
Expected cost of Alzheimer’s and dementia by 2050 (in 2025 dollars) if no treatment or cure is available1.
Pipeline
IGC Pharma’s pipeline bridges breakthroughs from AI-enhanced
early detection to IGC-AD1 and beyond, advancing Alzheimer’s
treatment frontiers.
In-depth insights,
real impact
“Science Spotlight” reveals our latest Alzheimer’s research, breakthroughs, and care innovations.
Resources
for Caregivers
This guide offers compassionate, evidence-based support for families caring for someone with Alzheimer’s disease. Written by leading neuropsychologists and enriched with real caregiver stories, it provides practical tips, emotional strategies, and step-by-step advice to understand the condition, manage daily challenges, and support emotional well-being. Supported by IGC Pharma, the book empowers caregivers with tips, strategies, and step-by-step guidance to improve care while also protecting their own well-being.
Investing in the Future:
IGC Pharma stands with families and vulnerable groups, investing in research, education, advocacy and Alzheimer’s awareness.
- 2025 Alzheimer’s disease facts and figures. Alzheimers Dement. 2025;21(4):e70235. Published 2025 Apr 29. doi:10.1002/alz.70235